Sigyn Therapeutics (SIGY) Accumulated Expenses (2020 - 2025)

Sigyn Therapeutics has reported Accumulated Expenses for 6 years, with the latest figure at $2.3 million in Q3 2025.

• Quarterly Accumulated Expenses rose 29.41% year-over-year to $2.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $2.3 million (up 29.41% YoY) and the FY2024 annual result came in at $1.9 million, up 136.05% from the prior year.
• Accumulated Expenses climbed to $2.3 million in Q3 2025 per SIGY's latest filing, from $2.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.3 million in Q3 2025 and troughed at $1072.0 in Q4 2021.
• A 5-year average of $800108.9 and a median of $295825.0 in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2022: Accumulated Expenses plunged 94.22% in 2021, then surged 2710.07% in 2022.
• Over 5 years, Accumulated Expenses stood at $1072.0 in 2021, then soared by 2710.07% to $30124.0 in 2022, then jumped by 2528.32% to $791754.0 in 2023, then jumped by 136.05% to $1.9 million in 2024, then increased by 21.98% to $2.3 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.3 million, $2.2 million, and $2.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.